Foghorn Therapeutics Inc. Net Income
Foghorn Therapeutics Inc. (FHTX) reported Net Income of -$7.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-06
- Foghorn Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$7.19M.
- Foghorn Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$19.88M.
- Foghorn Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$21.66M.
- Foghorn Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$15.85M.
- Foghorn Therapeutics Inc. net income (loss) attributable to parent for fiscal 2023 was -$98.43M.
- Foghorn Therapeutics Inc. net income (loss) attributable to parent for fiscal 2022 was -$108.88M.
- Foghorn Therapeutics Inc. net income (loss) attributable to parent for fiscal 2021 was -$101.32M.
- Foghorn Therapeutics Inc. net income (loss) attributable to parent for fiscal 2020 was -$68.80M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$7.19M 10-Q · filed 2026-08-06 | -$27.07M 10-Q · filed 2026-08-06 | -$48.73M derived: sum of 3 quarters · filed 2026-08-06 | -$64.58M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$19.88M 10-Q · filed 2026-08-06 | -$41.54M derived: sum of 2 quarters · filed 2026-08-06 | -$57.39M derived: sum of 3 quarters · filed 2026-08-06 | -$75.32M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$21.66M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | -$37.51M derived: sum of 2 quarters · filed 2026-04-30 | -$55.45M derived: sum of 3 quarters · filed 2026-08-06 | -$74.28M DEF 14A · filed 2026-04-30 | |
| 2025-09-30 | -$15.85M 10-Q · filed 2025-11-05 | -$33.78M derived: sum of 2 quarters · filed 2026-08-06 | -$52.62M 10-Q · filed 2025-11-05 | -$72.12M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$17.94M 10-Q · filed 2026-08-06 | -$36.77M 10-Q · filed 2026-08-06 | -$56.27M derived: sum of 3 quarters · filed 2026-08-06 | -$75.39M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$18.83M 10-Q · filed 2026-08-06 | -$38.34M derived: sum of 2 quarters · filed 2026-08-06 | -$57.46M derived: sum of 3 quarters · filed 2026-08-06 | -$80.44M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2024-12-31 | -$19.50M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | -$38.63M derived: sum of 2 quarters · filed 2026-04-30 | -$61.60M derived: sum of 3 quarters · filed 2026-04-30 | -$86.62M DEF 14A · filed 2026-04-30 | |
| 2024-09-30 | -$19.12M 10-Q · filed 2025-11-05 | -$42.10M derived: sum of 2 quarters · filed 2025-11-05 | -$67.12M 10-Q · filed 2025-11-05 | -$91.22M derived: sum of 4 quarters · filed 2025-11-05 | |
| 2024-06-30 | -$22.98M 10-Q · filed 2025-11-05 | -$47.99M 10-Q · filed 2025-08-05 | -$72.10M derived: sum of 3 quarters · filed 2025-11-05 | -$86.45M derived: sum of 4 quarters · filed 2025-11-05 | |
| 2024-03-31 | -$25.02M 10-Q · filed 2025-11-05 | -$49.12M derived: sum of 2 quarters · filed 2025-11-05 | -$63.47M derived: sum of 3 quarters · filed 2025-11-05 | -$92.95M derived: sum of 4 quarters · filed 2025-11-05 | |
| 2023-12-31 | -$24.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$38.45M derived: sum of 2 quarters · filed 2025-03-06 | -$67.94M derived: sum of 3 quarters · filed 2025-03-06 | -$98.43M 10-K · filed 2025-03-06 | |
| 2023-09-30 | -$14.35M 10-Q · filed 2024-11-04 | -$43.83M derived: sum of 2 quarters · filed 2024-11-04 | -$74.32M 10-Q · filed 2024-11-04 | -$103.21M derived: sum of 4 quarters · filed 2024-11-04 | |
| 2023-06-30 | -$29.49M 10-Q · filed 2024-11-04 | -$59.98M 10-Q · filed 2024-08-08 | -$88.86M derived: sum of 3 quarters · filed 2024-11-04 | -$114.63M derived: sum of 4 quarters · filed 2024-11-04 | |
| 2023-03-31 | -$30.49M 10-Q · filed 2024-11-04 | -$59.37M derived: sum of 2 quarters · filed 2024-11-04 | -$85.14M derived: sum of 3 quarters · filed 2024-11-04 | -$112.46M derived: sum of 4 quarters · filed 2024-11-04 | |
| 2022-12-31 | -$28.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$54.66M derived: sum of 2 quarters · filed 2024-03-07 | -$81.97M derived: sum of 3 quarters · filed 2024-03-07 | -$108.88M 10-K · filed 2024-03-07 | |
| 2022-09-30 | -$25.77M 10-Q · filed 2023-11-02 | -$53.08M derived: sum of 2 quarters · filed 2023-11-02 | -$80.00M 10-Q · filed 2023-11-02 | -$109.14M derived: sum of 4 quarters · filed 2023-11-02 | |
| 2022-06-30 | -$27.31M 10-Q · filed 2023-11-02 | -$54.23M 10-Q · filed 2023-08-04 | -$83.37M derived: sum of 3 quarters · filed 2023-11-02 | -$109.45M derived: sum of 4 quarters · filed 2023-11-02 | |
| 2022-03-31 | -$26.91M 10-Q · filed 2023-11-02 | -$56.06M derived: sum of 2 quarters · filed 2023-11-02 | -$82.14M derived: sum of 3 quarters · filed 2023-11-02 | -$105.25M derived: sum of 4 quarters · filed 2023-11-02 | |
| 2021-12-31 | -$29.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$55.22M derived: sum of 2 quarters · filed 2023-03-09 | -$78.33M derived: sum of 3 quarters · filed 2023-03-09 | -$101.32M 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$26.08M 10-Q · filed 2022-11-08 | -$49.19M derived: sum of 2 quarters · filed 2022-11-08 | -$72.18M 10-Q · filed 2022-11-08 | -$92.94M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | -$23.11M 10-Q · filed 2022-11-08 | -$46.10M 10-Q · filed 2022-08-09 | -$66.86M derived: sum of 3 quarters · filed 2022-11-08 | -$85.22M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-03-31 | -$22.99M 10-Q · filed 2022-11-08 | -$43.74M derived: sum of 2 quarters · filed 2022-11-08 | -$62.11M derived: sum of 3 quarters · filed 2022-11-08 | -$77.83M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2020-12-31 | -$20.76M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | -$39.13M derived: sum of 2 quarters · filed 2022-08-09 | -$54.85M derived: sum of 3 quarters · filed 2022-08-09 | -$68.80M 10-K/A · filed 2022-08-09 | |
| 2020-09-30 | -$18.37M 10-Q · filed 2021-11-09 | -$34.09M derived: sum of 2 quarters · filed 2021-11-09 | -$48.04M 10-Q · filed 2021-11-09 | -$63.33M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | -$15.72M 10-Q · filed 2021-11-09 | -$29.68M 10-Q · filed 2021-08-10 | -$44.97M derived: sum of 3 quarters · filed 2021-11-09 | -$58.06M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-03-31 | -$13.95M 10-Q · filed 2021-11-09 | -$29.24M derived: sum of 2 quarters · filed 2021-11-09 | -$42.34M derived: sum of 3 quarters · filed 2021-11-09 | ||
| 2019-12-31 | -$15.29M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$28.38M derived: sum of 2 quarters · filed 2021-03-18 | -$51.13M 10-K · filed 2021-03-18 | -$51.10M 10-Q · filed 2020-12-04 | |
| 2019-09-30 | -$13.09M 10-Q · filed 2020-12-04 | -$35.84M 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |